AngioDynamics (Nasdaq: ANGO ) reported earnings on July 11. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended May 31 (Q4), AngioDynamics beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly. Non-GAAP earnings per share shrank significantly. GAAP loss per share shrank.
Gross margins shrank, operating margins increased, net margins grew.
AngioDynamics chalked up revenue of $90.0 million. The five analysts polled by S&P Capital IQ predicted revenue of $86.4 million on the same basis. GAAP reported sales were 56% higher than the prior-year quarter's $57.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.07. The five earnings estimates compiled by S&P Capital IQ forecast $0.06 per share. Non-GAAP EPS of $0.07 for Q4 were 30% lower than the prior-year quarter's $0.10 per share. GAAP EPS were -$0.02 for Q4 versus -$0.27 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 49.1%, 490 basis points worse than the prior-year quarter. Operating margin was 6.3%, 490 basis points better than the prior-year quarter. Net margin was -1.0%, much better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $83.7 million. On the bottom line, the average EPS estimate is $0.03.
Next year's average estimate for revenue is $348.6 million. The average EPS estimate is $0.32.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 100 members out of 114 rating the stock outperform, and 14 members rating it underperform. Among 33 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 29 give AngioDynamics a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AngioDynamics is outperform, with an average price target of $12.38.
Is AngioDynamics the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add AngioDynamics to My Watchlist.